

Solving the last jigsaws to minimize risks, optimize costs and accelerate commercialization at Biosimilars North America

The 3rd annual Biosimilars North America by popular demand, will be heading back to Iselin, New Jersey, USA this November.

LONDON, UNITED KINGDOM, September 29, 2016 /EINPresswire.com/ -- It's without doubts that the biosimilars market present lucrative opportunities for pharmaceuticals and biotech companies. Over the last 12 months, market participants have witnessed revolutionary steps in the US to facilitate commercialization. It is now time to meet your industry colleagues to discuss how to commercialize biosimilars, industry partnership and corporate strategy, [interchangeability](#) impact on biosimilars, regulatory updates and much more.

SMi Group is delighted to have Edric Engert, Senior Vice President, Biosimilars from Teva Pharmaceuticals discussing Biosimilars – from aspiration to operations at the 3rd annual Biosimilars North America conference this November. Edric will focus on corporate strategy, portfolio strategy and organizational implications.

Considerations for commercial success will be presented by Molly Burich, Associate Director, Public Policy – Biosimilars, Pipeline, Reimbursement, Boehringer Ingelheim Pharmaceuticals. Molly will answer the big question of reimbursement of biosimilars in the US – what's the future and challenges?

Furthermore, Brad Jordan, Director, Regulatory Affairs and R&D Policy, Amgen Inc. will be discussing regulatory concerns for interchangeability. The questions to be answered – what's in a name? Differentiating European and US terms and policies. What are the concerns? Medically-guided switching vs. pharmacy substitution. What's the standard? Survey of perspectives from policy makers and industry.

Day one will address the regulatory updates, commercialization: lessons learned in Europe and worldwide, while Day two will explore the technological developments, commercialization strategies and market development, through a series of exciting panel discussions, presentations and



SMi's 3rd annual conference...

Biosimilars North America

16 - 17 November 2016



Renaissance Woodbridge Hotel,
Iselin, New Jersey, USA

workshops.

The truly global event will also include presentations and an overview from Europe, Canada, China and more. Attendees will learn how optimal regulatory environment can encourage biosimilars uptake, how to capitalize on the market growth of biosimilars, industry partnerships: key success factors in [biosimilar](#) space and much more.

Other speakers will include: Sandoz, Norwegian Medicines Agency, Vizient, Janssen R&D, Abzena, Harvest Moon Pharmaceuticals, Wyatt Health Management, Schwegman Lundberg Woessner, Abpro-US.

To find out more about the event please visit: www.biosimilars-northamerica.com/ein
\$100 Early bird is ending on 30th September!

To join as a delegate please contact Fateja Begum +44 (0) 20 7827 6184 or email fbegum@smi-online.co.uk

For sponsorship opportunities contact Alia Malick on +44 (0) 20 7827 6168 or email: amalick@smi-online.co.uk

---- END ----

About SMi Group: Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world's most forward thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at <http://www.smi-online.co.uk>

Anna Serazetdinova
SMi Group Ltd
+44702078276180
email us here

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases.

© 1995-2017 IPD Group, Inc. All Right Reserved.